Cargando…
Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines
Mycobacterium tuberculosis (M. tuberculosis) is an intracellular pathogen causing long-term infection in humans that mainly attacks macrophages and can escape from the immune system with the various mechanisms. The only FDA-approved vaccine against M. tuberculosis (MTB) is Mycobacterium bovis bacill...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295111/ https://www.ncbi.nlm.nih.gov/pubmed/35852636 http://dx.doi.org/10.1007/s00284-022-02949-8 |
_version_ | 1784749991523254272 |
---|---|
author | Valizadeh, Azar imani Fooladi, Abbas Ali Sedighian, Hamid Mahboobi, Mahdieh Gholami Parizad, Elaheh Behzadi, Elham Khosravi, Afra |
author_facet | Valizadeh, Azar imani Fooladi, Abbas Ali Sedighian, Hamid Mahboobi, Mahdieh Gholami Parizad, Elaheh Behzadi, Elham Khosravi, Afra |
author_sort | Valizadeh, Azar |
collection | PubMed |
description | Mycobacterium tuberculosis (M. tuberculosis) is an intracellular pathogen causing long-term infection in humans that mainly attacks macrophages and can escape from the immune system with the various mechanisms. The only FDA-approved vaccine against M. tuberculosis (MTB) is Mycobacterium bovis bacillus Calmette-Guérin (BCG). The protection of this vaccine typically lasts 10–15 years. Due to the increasing number of people becoming ill with MTB each year worldwide, the need to develop a new effective treatment against the disease has been increased. During the past two decades, the research budget for TB vaccine has quadrupled to over half a billion dollars. Most of these research projects were based on amplifying and stimulating the response of T-cells and developing the subunit vaccines. Additionally, these studies have demonstrated that secretory and immunogenic proteins of MTB play a key role in the pathogenesis of the bacteria. Therefore, these proteins were used to develop the new subunit vaccines. In this review, based on the use of these proteins in the successful new subunit vaccines, the PPE44, HSPX, CFP-10 and ESAT-6 antigens were selected and the role of these antigens in designing and developing new subunit vaccines against TB and for the prevention of TB were investigated. |
format | Online Article Text |
id | pubmed-9295111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-92951112022-07-19 Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines Valizadeh, Azar imani Fooladi, Abbas Ali Sedighian, Hamid Mahboobi, Mahdieh Gholami Parizad, Elaheh Behzadi, Elham Khosravi, Afra Curr Microbiol Review Article Mycobacterium tuberculosis (M. tuberculosis) is an intracellular pathogen causing long-term infection in humans that mainly attacks macrophages and can escape from the immune system with the various mechanisms. The only FDA-approved vaccine against M. tuberculosis (MTB) is Mycobacterium bovis bacillus Calmette-Guérin (BCG). The protection of this vaccine typically lasts 10–15 years. Due to the increasing number of people becoming ill with MTB each year worldwide, the need to develop a new effective treatment against the disease has been increased. During the past two decades, the research budget for TB vaccine has quadrupled to over half a billion dollars. Most of these research projects were based on amplifying and stimulating the response of T-cells and developing the subunit vaccines. Additionally, these studies have demonstrated that secretory and immunogenic proteins of MTB play a key role in the pathogenesis of the bacteria. Therefore, these proteins were used to develop the new subunit vaccines. In this review, based on the use of these proteins in the successful new subunit vaccines, the PPE44, HSPX, CFP-10 and ESAT-6 antigens were selected and the role of these antigens in designing and developing new subunit vaccines against TB and for the prevention of TB were investigated. Springer US 2022-07-19 2022 /pmc/articles/PMC9295111/ /pubmed/35852636 http://dx.doi.org/10.1007/s00284-022-02949-8 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Valizadeh, Azar imani Fooladi, Abbas Ali Sedighian, Hamid Mahboobi, Mahdieh Gholami Parizad, Elaheh Behzadi, Elham Khosravi, Afra Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines |
title | Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines |
title_full | Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines |
title_fullStr | Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines |
title_full_unstemmed | Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines |
title_short | Evaluating the Performance of PPE44, HSPX, ESAT-6 and CFP-10 Factors in Tuberculosis Subunit Vaccines |
title_sort | evaluating the performance of ppe44, hspx, esat-6 and cfp-10 factors in tuberculosis subunit vaccines |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295111/ https://www.ncbi.nlm.nih.gov/pubmed/35852636 http://dx.doi.org/10.1007/s00284-022-02949-8 |
work_keys_str_mv | AT valizadehazar evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines AT imanifooladiabbasali evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines AT sedighianhamid evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines AT mahboobimahdieh evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines AT gholamiparizadelaheh evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines AT behzadielham evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines AT khosraviafra evaluatingtheperformanceofppe44hspxesat6andcfp10factorsintuberculosissubunitvaccines |